Skip to main content

Table 1 Recipient demographics and perioperative outcomes

From: A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation

 

ATG (n = 15)

DZM (n = 15)

P value

Age (years)

58 ± 3

57 ± 3

0.9

Sex (male/female)

11/4

12/3

1.0

Diagnosis

   

 Idiopathic cardiomyopathy

11 (73%)

10 (67%)

1.0

 Other

4 (27%)

5 (33%)

1.0

Height (cm)

172 ± 2

172 ± 3

0.9

Weight (kg)

78 ± 3

83 ± 5

0.4

Body mass index (kg/m2)

26 ± 1

28 ± 2

0.4

Status

   

 1: Stable and waiting out of hospital

8 (53%)

9 (60%)

1.0

 2: Stable and waiting in hospital

3 (20%)

2 (13%)

1.0

 3: In hospital on Inotropic support

4 (27%)

3 (20%)

1.0

 4: Intubated

0 (0%)

1 (7%)

1.0

Diabetes mellitus

0 (0%)

2 (13%)

0.5

Lymphocytotoxic crossmatch

   

 Negative

15 (100%)

15 (100%)

1.0

CMV mismatch

   

 Negative recipient/Positive donor

1 (7%)

1 (7%)

1.0

EBV mismatch

   

 Negative recipient/Positive donor

0 (0%)

0 (0%)

-

Operative time (min)

333 ± 18

351 ± 20

0.5

Cardiopulmonary bypass time (min)

187 ± 10

194 ± 16

0.7

Intubation time (h)

96 ± 47

130 ± 55

0.7

Intensive care unit time (h)

264 ± 102

289 ± 96

0.9

Inotropic severity score

49 ± 6

65 ± 5

0.07

Total hospital length of stay (days)

29 ± 8

26 ± 6

0.8

  1. CMV: cytomegalovirus; EBV: Epstein-Barr virus.